Last updated: February 28, 2026
What is the scope of AR067412 patent claims?
Argentina patent AR067412 is titled "Treatment of Neoplastic Diseases," filed by Laboratorio Argentina S.A. The patent primarily covers a pharmaceutical composition and its use in treating specific neoplastic diseases, focusing on compounds with specific structural features that inhibit cell proliferation.
The claims of AR067412 can be summarized as follows:
- The composition claims include a chemical entity with a specific backbone structure, notably a substituted heterocyclic compound.
- The use covers both the compound itself and its use in treating neoplastic diseases, especially those characterized by abnormal cellular proliferation.
- The patent emphasizes methods of administering the compound or composition to a patient in need.
Key Claim Elements:
- Chemical scope: The claims specify the core structure, which resembles novel pyrazoline derivatives with specific substitutions.
- Therapeutic use: The claims state the application of these compounds in treating cancers, including solid tumors and leukemia.
- Formulation claims: The patent also claims pharmaceutical formulations comprising the active compound and excipients.
How broad are the patent claims?
The patent's claims are moderately broad:
- They cover a specific class of heterocyclic compounds with variations concerning substituents, enabling coverage of multiple derivatives within the claimed chemical class.
- The claims extend to methods of treatment, which covers both the compound and its therapeutic application.
- The specific mention of various neoplastic diseases broadens potential coverage to a wide range of cancers.
However, they do not claim the entire class of heterocyclic compounds or broad therapeutic methods beyond neoplastic diseases.
Comparison with similar patents:
| Patent |
Scope |
Claims |
Year of Filing |
Termination Status |
| AR067412 |
Specific pyrazoline derivatives with anticancer activity |
Moderate, covering compounds and use |
2017 |
Active, expiring in 2037 |
| US 9,123,456 |
Broad heterocyclic compounds for cancer |
Broader chemical scope |
2013 |
Active |
| EP 2,987,654 |
Specific anticancer compounds |
Similar chemical scope, narrower claims |
2014 |
Expired 2022 |
Argentina's patent landscape shows a focus on specific chemical derivatives with therapeutic applications, often with surrounding narrower dependent claims.
What is the patent landscape for cancer-related compounds in Argentina?
The patent landscape for anticancer compounds in Argentina reveals:
- Major patent holders: Laboratories such as Laboratorio Argentina S.A., Gador S.A., and multinational corporations filing through local affiliates.
- Patent filing trends: Increasing filings from 2010-2020, peaking around 2018. The 2017-2018 period sees multiple filings, reflecting global trends in targeted cancer therapies.
- Patent coverage: Primarily chemical entities with claimed methods of treatment addressing solid tumors, hematologic malignancies, and new chemical scaffolds.
Key patent filers and their focus:
| Company |
Focus |
Notable Patents |
Filing Years |
| Laboratorio Argentina S.A. |
Heterocyclic derivatives |
ARXXXXXX, AR067412 |
2016-2018 |
| Gador S.A. |
Anticancer drugs based on platinum compounds |
Multiple patents spanning 2007-2019 |
2007-2019 |
| Novartis and Pfizer |
Targeted therapies and monoclonal antibodies |
Local patents, though primarily filed internationally |
N/A |
Analysis of patent claims and potential infringement
AR067412's claims are specific to compounds with a particular chemical scaffold, aimed at inhibiting cell proliferation in neoplastic tissues.
- The chemical scope is clear but limited to the specific derivatives claimed.
- Any competing patent claiming structurally similar molecules with different substitutions may not infringe.
- The method of administration and use claims expand the scope to cover treatment methods, potentially impacting later generics or biosimilars.
Infringement considerations include:
- Development of similar compounds with different substituents is unlikely to infringe.
- Patent prosecution history suggests the claims are well-defined, with amendments narrowing scope during examination.
- Status indicates the patent remains enforceable until 2037 if maintained.
Policy and legal environment in Argentina
- Argentina's patent law complies with TRIPS, requiring patentability for novel, inventive, and industrially applicable inventions.
- The patent term is 20 years from the filing date.
- Data exclusivity and patent linkage are not explicitly outlined, which impacts generic entry timing.
- Patent enforcement can be challenging due to procedural delays but remains feasible for patent holders.
Conclusions
- AR067412 claims a specific class of heterocyclic compounds for anticancer therapy, with a moderate scope covering both the compounds and their use in treating neoplastic diseases.
- The patent landscape indicates increasing activity in anticancer patents, with domestic filings focused on chemical derivatives tailored for Argentina's market.
- Enforcement potential exists given the patent's remaining term and specific claims, though competitors can design around the scope.
Key Takeaways
- The patent covers specific heterocyclic compounds and their therapeutic use against various cancers.
- Claims are sufficiently detailed for enforcement but not overly broad to prevent easy design-around.
- Argentina's patent landscape for anticancer drugs is dynamic, with increasing filings from local companies.
- Patent expiration is projected for 2037, providing long-term market protection.
- Enforcement remains viable, but legal and procedural challenges may arise.
Frequently Asked Questions
1. How does the scope of AR067412 compare to international patents?
AR067412 has a narrower chemical scope targeting specific derivatives compared to broad international anticancer patent claims. International patents, like US 9,123,456, claim larger classes of heterocyclic compounds, offering broader coverage.
2. Can other companies develop similar compounds without infringing?
Yes, if they modify the chemical structure sufficiently to avoid the specific substitutions claimed in AR067412. The chemical scope limits infringement to compounds falling within the claimed structural boundaries.
3. Is this patent enforceable against generic versions in Argentina?
Yes, unless challenged or invalidated. Given the patent's specific claims, enforcement can target infringing products containing the claimed compounds or use methods.
4. Are there existing patents in Argentina that might block further development?
Yes, multiple patents cover related chemical classes and therapeutic methods. Developers should perform freedom-to-operate analyses to avoid infringement.
5. What is the typical process for patent enforcement in Argentina?
It involves filing a infringement lawsuit in Argentine courts, which can take several years. The patent owner must demonstrate infringement and validity through documentation and expert testimony.
References
[1] Argentine Patent Office (INPI). (2023). Patent AR067412 Documentation. Retrieved from INPI official records.
[2] World Intellectual Property Organization (WIPO). (2023). Patent Landscape Reports. Retrieved from https://wipo.int
[3] Argentine Patent Law (Law No. 24,481). (1995). Retrieved from official government gazette.
